Literature DB >> 27896896

Presumed tuberculous uveitis in non-endemic country for tuberculosis: case series from a New Zealand tertiary uveitis clinic.

Ken K Ng1, Mitzi Nisbet2, Erika M Damato1, Joanne L Sims1.   

Abstract

BACKGROUND: To describe the clinical spectrum of presumed tuberculous (TB) uveitis in a developed, non-endemic country of high immigrant population.
DESIGN: Retrospective review of a consecutive case series. PARTICIPANTS: All 39 patients diagnosed with presumed TB uveitis at the tertiary uveitis service in Auckland from 2007 to 2014.
METHODS: Clinical chart review. MAIN OUTCOME MEASURES: Patient demographics, risk factors, ophthalmic manifestations, management and outcome.
RESULTS: The median age was 37 years (interquartile range [IQR] 31-52) and 56% were female. The majority (97%) were born outside of New Zealand, and 77% had no TB-related history. Radiological abnormalities consistent with TB were evident in seven patients, including three who had culture positive pulmonary disease. Anterior uveitis was diagnosed in ten patients (26%), anterior and intermediate uveitis in eight (21%), posterior uveitis in 13 (33%) and panuveitis in eight (21%). Sixteen (41%) had retinal vasculitis, and five (13%) had multifocal serpiginoid choroiditis. Common complications included cataract (51%), ocular hypertension (36%), broad posterior synechiae (33%) and cystoid macular oedema (28%). Anti-TB treatment was initiated in 30 patients (76%). All but three patients completed the intended course of six to 12 months. Following anti-TB treatment, 67% remained in remission for at least 12 months, and all but two patients successfully stopped systemic steroids. The median initial and final visual acuity was 6/9 (IQR 6/6-6/18) and 6/6 (IQR 6/6-6/9), respectively.
CONCLUSIONS: Despite a wide range of ocular presentations and complications, our cohort demonstrated good remission rate and visual prognosis following anti-TB treatment in carefully selected patients.
© 2016 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  infection; inflammation; tuberculosis; uveitis

Mesh:

Year:  2017        PMID: 27896896     DOI: 10.1111/ceo.12881

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

1.  Asymptomatic occlusive retinal vasculitis in newly diagnosed active tuberculosis.

Authors:  Christopher Bartimote; Samantha Fraser-Bell; Hamish Dunn
Journal:  Respir Med Case Rep       Date:  2021-06-24

2.  Early treatment of tuberculous uveitis improves visual outcome: a 10-year cohort study.

Authors:  Luis Anibarro; Eliana Cortés; Ana Chouza; Alberto Parafita-Fernández; Juan Carlos García; Alberto Pena; Carlos Fernández-Cid; África González-Fernández
Journal:  Infection       Date:  2018-06-04       Impact factor: 3.553

3.  The Association between QuantiFERON-TB Gold Test and Clinical Manifestations of Uveitis in the United States.

Authors:  Mehmet Yakin; Natasha Kesav; Shuk Kei Cheng; Sonny Caplash; Sapna Gangaputra; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2021-05-02       Impact factor: 5.488

4.  Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration.

Authors:  William J Connors; Dina A Fisher; Dennis Y Kunimoto; Julie M Jarand
Journal:  BMC Infect Dis       Date:  2019-01-29       Impact factor: 3.090

5.  Treatment Outcome of Tubercular Uveitis in a High TB and HIV Setting: A Prospective Cohort Study.

Authors:  Hassan Dawood Alli; Naseer Ally; Ismail Mayet; Lavania Joseph; Shaheed Omar; Shabir Madhi
Journal:  Clin Ophthalmol       Date:  2021-12-30

6.  Comprehensive analysis of vitreous specimens for uveitis classification: a prospective multicentre observational study.

Authors:  Kazuichi Maruyama; Tohru Inaba; Sunao Sugita; Ryo Ichinohasama; Kenji Nagata; Shigeru Kinoshita; Manabu Mochizuki; Toru Nakazawa
Journal:  BMJ Open       Date:  2017-11-16       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.